Related Experiment Video
Updated: Sep 27, 2025
Monitoring the Wall Mechanics During Stent Deployment in a Vessel
Published on: May 8, 2012
Mathematical modelling of endovascular drug delivery: Balloons versus stents
Javier Escuer1, André Fensterseifer Schmidt2, Estefanía Peña3
1Aragón Institute for Engineering Research (I3A), University of Zaragoza, Spain.
Insights
Drug-coated balloons (DCBs) offer a promising alternative to permanent drug-eluting stents (DESs) for treating coronary artery disease. This study introduces a computational model to compare drug delivery from DCBs and DESs, aiding in the design of safer and more effective devices.
Area of Science:
- Biomedical Engineering
- Cardiovascular Research
- Computational Modeling
Background:
- Drug-eluting stents (DESs) are standard for coronary artery disease (CAD), but their permanent nature poses challenges like delayed healing and difficulties in treating in-stent restenosis (ISR).
- Drug-coated balloons (DCBs) are emerging as alternatives to DESs for de novo lesions, offering potential solutions to DES limitations.
- Concerns regarding DCB safety and efficacy persist, including the need for high drug loading due to short delivery windows and a shift towards limus-eluting balloons due to safety signals with paclitaxel.
Purpose of the Study:
- To develop and present a computational model for investigating and comparing drug delivery from DCBs and DESs.
- To simulate drug delivery dynamics, considering factors like drug binding, diffusion, advection, and arterial wall properties.
- To evaluate the safety and efficacy of different DCB platforms, drugs, and application parameters against DES performance.
Main Methods:
- A 2D-axisymmetric computational framework was developed to model drug delivery.
- The model incorporates nonlinear drug binding (specific and non-specific), diffusion, and advection within a multilayer arterial wall.
- Simulations were performed to analyze drug delivery from various balloon platforms, assess the impact of DCB application time and pressure, compare sirolimus and paclitaxel elution, and contrast DCB with DES performance.
Main Results:
- The computational model successfully simulated drug delivery from DCBs and DESs, providing insights into drug distribution and tissue concentration.
- Key performance indicators, including drug content in tissue (DC) and specific binding site saturation (%SBSS), were used to compare devices.
- Results highlighted the trade-offs between DCBs and DESs regarding safety and efficacy, suggesting potential for DCB design optimization.
Conclusions:
- The developed computational model serves as a valuable tool for understanding and optimizing drug delivery from both DCBs and DESs.
- DCBs present a viable alternative to DESs, with potential for improved safety and efficacy profiles through careful design and drug selection.
- Further research and development guided by computational modeling can lead to DCBs that match or exceed the performance of current DESs in treating coronary artery disease.
Abstract:
The most common treatment for obstructive coronary artery disease (CAD) is the implantation of a permanent drug-eluting stent (DES). Not only has this permanency been associated with delayed healing of the artery, but it also poses challenges when treating subsequent re-narrowing due to in-stent restenosis (ISR). Drug-coated balloons (DCBs) provide a potential solution to each of these issues. While their use has been primarily limited to treating ISR, in recent years, DCBs have emerged as an attractive potential alternative to DESs for the treatment of certain de novo lesions. However, there remain a number of concerns related to the safety and efficacy of these devices. Firstly, unlike DESs, DCBs necessitate a very short drug delivery window, favouring a higher drug loading. Secondly, while the majority of coronary DCBs in Europe are coated with paclitaxel, the potential mortality signal raised with paclitaxel DCBs in peripheral interventions has shifted efforts towards the development of limus-eluting balloons. The purpose of this paper is to provide a computational model that allows drug delivery from DCBs and DESs to be investigated and compared. We present a comprehensive computational framework that employs a 2D-axisymmetric geometry, incorporates two nonlinear phases of drug binding (specific and non-specific) and includes the influence of diffusion and advection, within a multilayer arterial wall. We utilise this framework to (i) simulate drug delivery from different types of balloon platform; (ii) explore the influence of DCB application time; (iii) elucidate the importance on release kinetics of elevated pressure during DCB application; (iv) compare DCB delivery of two different drugs (sirolimus and paclitaxel) and; (v) compare simulations of DESs versus DCBs. Key measures of comparison are related to safety (drug content in tissue, DC) and efficacy (specific binding site saturation, %SBSS) markers. Our results highlight the pros and cons of each device in terms of DC and %SBSS levels achieved and, moreover, indicate the potential for designing a DCB that gives rise to sufficiently similar safety and efficacy indicators as current commercial DESs.
